Roche at ACR, 04-08 Nov 2017 San Diego, CA
Welcome to Roche at ACR 2017
Worldwide, the American College of Rheumatology’s Annual Meeting is recognised to be the premier educational event for physicians, healthcare professionals, and scientists specialised in rheumatology and musculoskeletal diseases. The congress offers the opportunity to exchange the most up-to-date scientific knowledge including prevention, diagnosis, treatment and latest investigations.
ACR 2017 - Nov 4-8, San Diego, California
Discover Roche’s highlights from this year’s Annual Meeting, including the latest clinical trial data from different rheumatological disease areas.
Latest on Medically from ACR 2017
Systemic Sclerosis: A rare, progressive,immune-mediated disease
This module provides information on symptoms of diffuse cutaneous (dc) and limited cutaneous (lc) SSc, and on how this life-threatening disease with high unmet need severely affects patient lives.
ACR 2017 oral presentation- Health-Related Quality of Life in Patients With Giant Cell Arteritis Treated With Tocilizumab in a Phase 3 Randomized Controlled Trial: GiACTA
The study evaluates Health-related Quality of life outcomes measure in the 52 week Phase III study of TCZ in GCA.
ACR 2017 oral presentation- Sustained Response Following Discontinuation of Methotrexate in Patients With Rheumatoid Arthritis Treated With Subcutaneous Tocilizumab: Results From a Randomized Controlled Trial (COMP-ACT)
The study evaluates whether TCZ-MONO is non-inferior to TCZ + MTX in maintaining clinical response in RA patients who achieve low disease activity (LDA) following treatment with the combination of TCZ + MTX.
ACR 2017 oral presentation- MRI Results Following Discontinuation of Methotrexate in Patients with Rheumatoid Arthritis Treated With Subcutaneous Tocilizumab: Results From a Randomized Controlled Trial
The study assesses joint damage between RA patients in the COMP-ACT trial who achieved LDAS activitiy with TCZ + MTX and continued TCZ + MTX vs. discontinued MTX (TCZ Monotherapy).
ACR 2017 poster- Patient-Reported Outcomes Following Discontinuation of Methotrexate in Patients With Rheumatoid Arthritis Treated With Subcutaneous Tocilizumab: Results From a Randomized Controlled Trial
Patient-reported outcomes (PROs) from the COMP-ACT study.
ACR 2017 poster- Tocilizumab Inhibits Progression of Erosive Joint Damage in Early Rheumatoid Arthritis More Effectively Than Step-up Methotrexate Therapy
Evaluation of the effect of the treatment strategies on progression of erosions and joint space narrowing (JSN) within the Phase IV U-ACT-EARLY study.